Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis

The Pharmacogenomics Journal volume 14, pages 432–438 (2014)Cite this article

Subjects

Abstract

Relapse is a threat in patients treated for acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) activity may affect the sensitivity of patients to folate-based chemotherapeutic drugs, thus influencing the relapse risk. Two polymorphisms of the gene encoding MTHFR, C677T and A1298C, alter MTHFR enzyme activity and may be associated with ALL relapse. The aim of this meta-analysis was to clarify the correlation between the C677T and A1298C polymorphisms and ALL relapse. To this end, data were collected from studies of the association between these two polymorphisms and ALL relapse. Analysis of the data revealed a serious contradiction among the results. A recessive model demonstrated that the ALL relapse risk was significantly increased in carriers of the 677 TT genotype, especially for pediatric ALL, but was unaffected by the A1298C polymorphism. These findings confirm that the MTHFR C677T polymorphism could be considered as a good marker of the pediatric ALL relapse risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. De Mattia E, Toffoli G . C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45: 1333–1351.

    Article  CAS  PubMed  Google Scholar 

  2. de Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; 106: 717–720.

    Article  CAS  PubMed  Google Scholar 

  3. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35: 572–579.

    CAS  PubMed  Google Scholar 

  5. Krajinovic M, Costea I, Chiasson S . Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359: 1033–1034.

    Article  CAS  PubMed  Google Scholar 

  6. Pui CH, Evans WE . Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178.

    Article  CAS  PubMed  Google Scholar 

  7. Thomas X, Le QH . Prognostic factors in adult acute lymphoblastic leukemia. Hematology 2003; 8: 233–242.

    Article  PubMed  Google Scholar 

  8. Cheok MH, Evans WE . Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117–129.

    Article  CAS  PubMed  Google Scholar 

  9. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151–4157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bailey LB, Gregory JR . Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999; 129: 919–922.

    Article  CAS  PubMed  Google Scholar 

  11. Karas KN, Milek M, Jazbec J, Mlinaric-Rascan I . 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res 2009; 33: 1344–1348.

    Article  Google Scholar 

  12. Eissa DS, Ahmed TM . C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 2013; 24: 181–188.

    CAS  PubMed  Google Scholar 

  13. Safarinejad MR, Shafiei N, Safarinejad S . Methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C and G1793A polymorphisms: association with risk for clear cell renal cell carcinoma and tumour behaviour in men. Clin Oncol (R Coll Radiol) 2012; 24: 269–281.

    Article  CAS  Google Scholar 

  14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113.

    Article  CAS  PubMed  Google Scholar 

  15. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis ER et al. The 1298A—>C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409–415.

    Article  CAS  PubMed  Google Scholar 

  16. Chiusolo P, Reddiconto G, Farina G, Mannocci A, Fiorini A, Palladino M et al. MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007; 31: 1669–1674.

    Article  CAS  PubMed  Google Scholar 

  17. D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011; 68: 1339–1346.

    Article  CAS  PubMed  Google Scholar 

  18. El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN . Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012; 29: 2053–2062.

    Article  CAS  PubMed  Google Scholar 

  19. Tantawy AA, El-Bostany EA, Adly AA, Abou EAM, El-Ghouroury EA, Abdulghaffar EE . Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2010; 21: 28–34.

    Article  CAS  PubMed  Google Scholar 

  20. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482–2487.

    Article  CAS  PubMed  Google Scholar 

  21. Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M et al. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer 2012; 58: 695–700.

    Article  PubMed  Google Scholar 

  22. Pietrzyk JJ, Bik-Multanowski M, Skoczen S, Kowalczyk J, Balwierz W, Alicja Chybicka et al. Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res 2011; 35: 1464–1466.

    Article  CAS  PubMed  Google Scholar 

  23. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105: 4752–4758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chiusolo P, Giammarco S, Bellesi S, Metafuni E, Piccirillo N, De Ritis D et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69: 691–696.

    Article  CAS  PubMed  Google Scholar 

  25. Aldrin M, Raastad R, Tvete IF, Berild D, Frigessi A, Leegaard T et al. Antibiotic resistance in hospitals: a ward-specific random effect model in a low antibiotic consumption environment. Stat Med 2013; 32: 1407–1418.

    Article  PubMed  Google Scholar 

  26. Wang Y, Localio R, Rebbeck TR . Evaluating bias due to population stratification in case-control association studies of admixed populations. Genet Epidemiol 2004; 27: 14–20.

    Article  PubMed  Google Scholar 

  27. Wacholder S, Rothman N, Caporaso N . Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92: 1151–1158.

    Article  CAS  PubMed  Google Scholar 

  28. Millikan RC . Re: population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2001; 93: 156–158.

    Article  CAS  PubMed  Google Scholar 

  29. Nachman J . Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 2005; 130: 166–173.

    Article  PubMed  Google Scholar 

  30. Rowe JM . Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010; 150: 389–405.

    PubMed  Google Scholar 

  31. Pui CH, Relling MV, Evans WE . Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 741–756.

    Article  CAS  PubMed  Google Scholar 

  32. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A . Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4: 66–72.

    Article  CAS  PubMed  Google Scholar 

  33. Lobato-Mendizabal E, Lopez-Martinez B, Ruiz-Arguelles GJ . A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia. Rev Invest Clin 2003; 55: 31–35.

    PubMed  Google Scholar 

  34. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC . Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450–455.

    Article  CAS  PubMed  Google Scholar 

  35. Zheng M, Yue L, Zhang H, Yang C, Xie C . [Association of single nucleotide polymorphism of methylenetetrahydrofolate reductase gene with susceptibility to acute leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2013; 30: 451–455.

    CAS  PubMed  Google Scholar 

  36. Yang L, Hu X, Xu L . Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 2012; 33: 1445–1454.

    Article  CAS  PubMed  Google Scholar 

  37. Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K et al. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma, advance online publication, 3 September 2013 doi:10.3109/10428194.2013.825902(e-pub ahead of print).

  38. Niedzielska E, Weclawek-Tompol J, Matkowska-Kocjan A, Chybicka A . The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. Adv Clin Exp Med 2013; 22: 579–584.

    PubMed  Google Scholar 

  39. Robien K, Ulrich CM . 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571–582.

    Article  PubMed  Google Scholar 

  40. Ongaro A, De Mattei M, Della PM, Rigolin G, Ambrosio C, Di Raimondo F et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 2009; 94: 1391–1398.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Rosenblatt DS . Methylenetetrahydrofolate reductase. Clin Invest Med 2001; 24: 56–59.

    CAS  PubMed  Google Scholar 

  42. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F et al. Effect of methylenetetrahydrofolate reductase 677C—>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103: 294–299.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Fundamental Research Funds for the Central Universities (No. 08143047) of China.

Author information

Author notes

  1. H-R He, S-Y Chen and H-S You: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China

    H-R He, S-Y Chen, H-S You, S-S Hu, J-Y Sun, Y-L Dong & J Lu

Authors
  1. H-R He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S-Y Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H-S You
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S-S Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J-Y Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-L Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Y-L Dong or J Lu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, HR., Chen, SY., You, HS. et al. Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis. Pharmacogenomics J 14, 432–438 (2014). https://doi.org/10.1038/tpj.2014.10

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2014.10

Search

Advanced search

Quick links